Chimeric Antigen Receptor (CAR) T cells combine the MHC-independent tumor recognition of the tumor-targeting domain (i.e., antibody or receptor ligand) with the cytolytic potency of a T cell. This evidence concerns the gene HLA-C and neoplasm.